TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03986255

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: The participant is placed lateral or sitting position. Fluoroscopy may be used to guide sampling. Full aseptic technique is used throughout.~The skin is prepared with either 2% chlorhexidine/70% alcohol or iodine. 1% lidocaine is used for skin local anesthesia an entry point is identified, this may be done using fluoroscopy. This will be at the lowest intervertebral foramina interspace to minimize the risk of spinal cord injury. A small amount to head up tilt will be allowed to optimize CSF flow.~Sampling is done using a needle through needle technique. An epidural needle is used to identify the epidural space using loss of resistance to saline technique. A spinal needle (26G) is then passed through the epidural needle into the subarachnoid space. Correct entry is noted once CSF is noted in the needle hub and 5 ml taken. This sample is then sent off for analysis.~Once the CSF is sampled, the needle is removed and pressure applied to the skin entry point.
Study: NCT02881034

Intervention type: DRUG
Intervention: Triple therapy
Study: NCT00944034

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ with routine vaccinations
Description: rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ with routine vaccinations
Description: rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ
Description: rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ
Description: rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ with routine vaccinations
Description: rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ with routine vaccinations
Description: rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 18 months of age
Study: NCT04250662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS with guided imagery
Description: The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have 20 minutes of stimulation with 25 minutes of guided imagery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS alone (no guided imagery)
Description: The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. Active tDCS arm alone without guided imagery, will have 20 minutes of tDCS stimulation without guided imagery.
Study: NCT01447667

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance elastography
Description: Magnetic resonance elastography before RFA and Liver biopsy of 2 HCC tissue and 2 non tumor liver parenchyma tissue
Study: NCT00944034

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: two doses of rMenB+OMV NZ
Description: two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ with routine vaccinations
Description: rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: two doses of rMenB+OMV NZ
Description: two catch-up doses of rMenB+OMV NZ at 18 and 20 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ
Description: rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: two doses of rMenB+OMV NZ
Description: two catch-up doses of rMenB+OMV NZ at 24 and 26 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ with routine vaccinations
Description: rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 (Group 3a), 18 (Group 3b) or 24 (Group 3c) months of age
Study: NCT03568890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban, dabigatran, apixaban, or edoxaban
Description: Duration of treatment: 60 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel -75 mg/day
Description: Duration of treatment: 60 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose aspirin -80 to 125 mg/day-
Description: Duration of treatment: 60 days
Study: NCT00384241

Intervention type: BEHAVIORAL
Intervention: Induced Stress
Description: Participation in an active coping task by playing a video game against another participant.

Intervention type: PROCEDURE
Intervention: Buccal Swab
Description: One Buccal swab collected from each parent
Study: NCT01072292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: CBT-I is a six week program designed to improve sleep quality in people with COPD.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-I
Description: CBT-I is a six week program designed to improve sleep quality in people with COPD.
Study: NCT01868984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel solution treatment of each lesion encountered will be attempted until the 20 mg Paclitaxel dose limit is met. The volume administered will depend on the diameter and length of the venous outflow segment.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard Therapy
Description: Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (\>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (\>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).
Study: NCT00510276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine hydrochloride
Description: 20-50 mg, twice a day per by mouth for 12 weeks, followed by up to an additional 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice a day, by mouth for 12 weeks
Study: NCT02427048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback with Peer Comparison
Description: Email detailing adherence to CAP and SS CPG for every month since start of study. Physicians will be provided individualized feedback and given patient identifiers for each patient that received non-adherent care.
Study: NCT02250209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is given by intravenous infusion at 440mg on day 0every 3 weeks. Number of cycles: 14\~16 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 800\~1000 mg/m² is given orally twice a day for 14 days followed by a 1-week rest.~Number of cycles: 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin is given by intravenous infusion at 130 mg/m2 on day 1 every 3 weeks.~Number of cycles: 8 cycles.
Study: NCT04250662

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS with guided imagery
Description: The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus sham tDCS arm will have 30 seconds of tDCS stimulation with 25 minutes of guided imagery.
Study: NCT02123290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSM265 xmg
Description: Dose of DSM265 to be determined based on the results of the first cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSM265 ymg
Description: Dose of DSM265 to be determined based on the results of the second cohort
Study: NCT02538484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Aromatase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Aromatase inhibitor

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: Omega-3 free fatty acid

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: Omega-3 free fatty acid
Study: NCT01961544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Description: 1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days
Study: NCT02327091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alfacalcidol
Description: One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo
Study: NCT00701714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX575 recombinant human erythropoietin alfa
Description: Solution for injection (s.c.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ERYPO
Description: Solution for injection (s.c.)
Study: NCT04250662

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS alone (no guided imagery)
Description: The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. Sham tDCS alone arm will have 30 seconds of tDCS stimulation without guided imagery.
Study: NCT03416283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Monitoring
Description: Remote BP monitoring and medication adherence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Monitoring + Social Support
Description: Remote BP monitoring and medication adherence with enhanced support from a support partner (facilitated cheerleading)
Study: NCT01363687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic postconditioning
Description: Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the upper limb free of arteriovenous fistula and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
Study: NCT03825913

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Training sessions will include a split routine based on the day of the week.~* Session 1 (e.g. Tuesday) - aerobic exercise (20-30 min) followed by resistance training (10 stacked-weight machines: leg press, leg extension, leg curl, chest press, latissimus pull, shoulder press, seated row, triceps press, biceps curl, and chest fly) for 1-2 sets of 8-12 repetitions.~* Session 2 (e.g. Thursday) - resistance bands and body weight exercises (4-6 exercises, 2 sets of 10-20 repetitions) followed by core exercises (2-3 sets of 10-20 repetitions) and aerobic training (20-30 min) at the end.~The starting training intensities will be at 50-55% of each individual's estimated maximum heart rate for aerobic exercise and one-repetition maximum for resistance training (assessed at baseline only for chest press and leg press). We plan a 5% monthly increase in the intensity to reach 65-70%% of one's maximum efforts by the end of the intervention.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Wellness Intervention
Description: In our setting, ten lectures in nutrition, exercise and various complementary and integrative medicine topics (e.g. acupuncture and Chinese medicine, mindfulness, quality sleep, etc.) were implemented among non-cancer individuals and modified based on their feedback.
Study: NCT01876576

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clear liquids
Description: Clear liquids

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low residue breakfast and lunch
Description: Low residue
Study: NCT02139553

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhythmic rehabilitation
Description: Stroke patients have 12 rehabilitation sessions on a planar rehabilitation robot, Reaplan, focussed on rhythmic arm movements.
Study: NCT03635359

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: analysis of cell-free DNA in maternal plasma

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: analysis of cell-free DNA in maternal plasma
Study: NCT00467220

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: calorie restriction
Description: Subjects in the calorie restriction arm and the alternate day fasting arm will be asked to follow a menu plan, for three months, that includes some level of calorie restriction.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: calorie restriction
Description: Subjects in the calorie restriction arm and the alternate day fasting arm will be asked to follow a menu plan, for three months, that includes some level of calorie restriction.
Study: NCT01582672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Standard treatment for Renal Cell Carcinoma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-003
Description: Autologous Dendritic Cell product. Intradermal injections; 8 injections in the 1st year followed by quarterly boosters.
Study: NCT01389102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol transdermal one 90 μL spray
Description: Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol transdermal spray, two 90 μL sprays
Description: Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol transdermal three 90 μL sprays
Description: Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal two 90 μL sprays
Description: Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal three 90 μL sprays
Description: Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal one 90 μL spray
Description: Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
Study: NCT01461850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy + Interval Debulking Surgery
Description: Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo only to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. After neoadjuvant chemotherapy interval debulking surgery will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Debulking Surgery + Adjuvant Chemotherapy
Description: Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. Then, an attempt of laparotomic cytoreduction will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.
Study: NCT01416246

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractionated Stem Cell Infusions
Description: Following enrollment patients will be treated with melphalan intravenously (IV) through a central venous catheter (CVC) over 30 minutes at 200mg/m2 or 140mg/m2 (if creatinine clearance is \< or = to 50 and/or age \> 70 years) on day -2. Following 24 hours of rest, the first dose of CD34+ stem cell will be administered on day 0 (2.5-5 x 106 CD 34+ stem cells/kg)+/- 0.5 x 106 CD34+ stem cells/kg), followed by 3 additional doses of CD 34+ stem cells (1.5-2.5 x 106 CD 34+ stem cells/kg)+/- 0.5 x 106 CD34+ stem cells/kg) on days +2, +4, and +6. Pegfilgrastim 6μg will be administered on day +1. Filgrastim 5μg/kg will be 12-24 hours after the 2nd-4th stem cell infusions. There will be a +/- 1 day window for the Day +2, +4, and +6 infusions to accommodate infusions that occur over the weekend or on holidays.
Study: NCT05034653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: During fasting day, no food or drink allowed from dawn to dusk

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Plate
Description: Quarter-quarter-half meal concept

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Plate
Description: Quarter-quarter-half meal concept
Study: NCT04634305

Intervention type: PROCEDURE
Intervention: Total elbow arthroplasty
Description: Total elbow arthroplasty by a single operator
Study: NCT04471285

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: acupuncture
Study: NCT04439539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 injection will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 injection will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN-alpha-2a
Description: PegIFN-alpha-2a injection will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN-alpha-2a
Description: PegIFN-alpha-2a injection will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Description: Tenofovir disoproxil film-coated tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Description: Tenofovir disoproxil film-coated tablet will be administered orally.
Study: NCT04471285

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sham acupuncture
Study: NCT03995329

Intervention type: OTHER
Group type: OTHER
Intervention: IQOS
Description: Acute effects of IQOS on pulmonary function, oxygen saturation, exhaled CO, heart rate and arterial blood pressure.
Study: NCT01604356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Description: Ten treatment sessions at our center during a two week period (5 sessions per week). Each session will last approximately 30 minutes. The intervention will involve the placement of acupuncture needles in a standard set of points across all patients, located on the head, around the eyes, on the abdomen, on the hands, feet, arms and legs. An electro-acupuncture device \[Transcutaneous electrical nerve stimulator (TENS) unit by Lhasa OMS Inc.; model AWQ-104L\] and will be used on four of the acupuncture points (two per session) located on the forehead, and side of the face/temple.